RET基因与肿瘤

doi:10.3760/cma.j.issn.1673-422X.2015.07.014

摘要/Abstract

摘要： RET基因与人类多种肿瘤的发生密切相关，是一种重要的癌基因。RET相关肿瘤的发病机制主要是RET基因突变和野生型RET基因的异常表达。激活的RET蛋白通过多种信号通路参与不同肿瘤细胞的增殖、凋亡、侵袭，影响肿瘤的发生发展。

Abstract: RET gene is an important oncogene, which is closely associated with the development of various types of human tumors. The mainly mechanisms of RET gene associated tumor are mutation and overexpression of wild type. Activated RET protein participates in the proliferation, apoptosis, metastasis through some signal pathways and influences the tumorigenesis and development.

Key words: Neoplasms, Therapy, RET gene

谢微微，常建华. RET基因与肿瘤[J]. 国际肿瘤学杂志, 2015, 42(7): 529-531.

Xie Weiwei, Chang Jianhua. RET gene and tumor[J]. Journal of International Oncology, 2015, 42(7): 529-531.

参考文献

［1］ Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from wholegenome and transcriptome sequencing［J］. Genome Res, 2012, 22（3）: 436-445. ［2］ American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer［J］. Thyroid, 2009, 19(11): 1167-1214. ［3］ Carr LL, Mankoff DA, Goulart BH, et al. Phase Ⅱ study of daily sunitinib in FDGPETpositive, iodinerefractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation［J］. Clin Cancer Res, 2010, 16(21): 5260-5268. ［4］ Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer［J］. Clin Cancer Res, 2013, 19(3): 524-529. ［5］ Pao W, Girard N. New driver mutations in nonsmallcell lung cancer［J］. Lancet Oncol, 2011, 12(2): 175-180. ［6］ Paziewska A, Harris PD, Zwolińska L, et al. Recombination within and between species of the alpha proteobacterium Bartonella infecting rodents［J］. Microb Ecol, 2011, 61(1): 134-145. ［7］ Cai W, Su C, Li X, et al. KIF5BRET fusions in Chinese patients with nonsmall cell lung cancer［J］. Cancer, 2013, 119(8): 1486-1494. ［8］ Kohno T, Ichikawa H, Totoki Y, et al. KIF5BRET fusions in lung adenocarcinoma［J］. Oncol Rep, 2012, 28(4): 1187-1192. ［9］ Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of nonsmallcell lung cancer［J］. J Clin Oncol, 2012, 30(35): 4352-4359. ［10］ Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer［J］. Nat Med, 2012, 18(3): 378381. ［11］ Pao W, Hutchinson KE. Chipping away at the lung cancer genome［J］. Nat Med, 2012, 18（3）: 349-351. ［12］ Tsuta K, Kohno T, Yoshida Al, et al. RETrearranged nonsmallcell lung carcinoma: a clinicopathological and molecular analysis［J］. Br J Cancer, 2014, 110(6): 1571-1578. ［13］ Dacic S, Luvison A, Evdokimova V, et al. RET rearrangements in lung adenocarcinoma and radiation［J］. J Thorac Oncol, 2014, 9(1): 118-120. ［14］ Marotta V, Guerra A, Sapio MR, et al. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint［J］. Eur J Endocrinol, 2011, 165(4): 499-507. ［15］ MinoKenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALKrearranged lung adenocarcinomas by standard immunohistochemistry［J］. Clin Cancer Res, 2010, 16(5): 1561-1571. ［16］ Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in nonsmall cell lung carcinoma: IHC score algorithm for FISH［J］. J Thorac Oncol, 2011, 6(3): 459-465. ［17］ Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies［J］. Nat Med, 2012, 18(3): 382-384. ［18］ Suzuki M, Makinoshima H, Matsumoto S, et al. Identification of a lung adenocarcinoma cell line with CCDC6RET fusion gene and the effect of RET inhibitors in vitro and in vivo［J］. Cancer Sci, 2013, 104(7): 896-903. ［19］ Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusionpositive lung adenocarcinomas［J］. Cancer Discov, 2013, 3(6): 630-635. ［20］ Gautschi O, Zander T, Keller FA, et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib［J］. J Thorac Oncol, 2013, 8(5): e43-44. ［21］ Morandi A, Martin LA, Gao Q, et al. GDNFRET signaling in ERPositive breast cancers is a key determinant of response and resistance to aromatase inhibitors［J］. Cancer Res, 2013, 73(12): 3783-3795. ［22］ PlazaMenacho I, Morandi A, Robertson D, et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance［J］. Oncogene, 2010, 29(33): 4648-4657. ［23］ Morandi A, PlazaMenacho I, Isacke CM. RET in breast cancer: functional and therapeutic implications［J］. Trends Mol Med, 2011, 17(3): 149-157. ［24］ Gattelli A, Nalvarte I, Boulay A, et al. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells［J］. EMBO Mol Med, 2013, 5(9): 1335-1350. ［25］ Cavel O, Shomron O, Shabtay A, et al. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor［J］. Cancer Res, 2012, 72(22): 5733-5743. ［26］ Wiedmann MW, Mssner J. Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors［J］. Clin Med Insights Oncol, 2012, 6: 381-393. ［27］ Luo Y, Tsuchiya KD, Ⅱ Park D, et al. RET is a potential tumor suppressor gene in colorectal cancer［J］. Mol Oncol, 2013, 32(16): 2037-2047.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.